Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. files a Prospectus Supplement to its Form S-1 registering up to 9,103,796 shares of common stock for resale by selling stockholders. The supplement attaches a Form 8-K disclosing that the company elected to discontinue further development contributions to v2vmedtech, inc., triggering termination of a related Development Agreement upon payment of a $400,000 break fee. The company states it does not expect these actions to have a material adverse effect on consolidated financial position or liquidity.
Anteris Technologies Global Corp., through its subsidiary Anteris Technologies Corporation, has elected to discontinue additional development contributions under its Contribution and Stock Purchase Agreement with v2vmedtech, inc., following completion of Stage 1 and during Stage 2 of the development program.
As a result, the related Development Agreement dated April 18, 2023 will terminate upon payment of a $400,000 break fee. Anteris states it does not expect this discontinuation of contributions and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.
BlackRock, Inc. reports beneficial ownership of 4,879,068 shares of ANTERIS TECHNOLOGIES GLOBAL CORP common stock, representing 5.01% of the class as of 03/31/2026. The filing lists sole voting power for 4,810,606 shares and sole dispositive power for 4,879,068 shares. The Schedule 13G was signed by Spencer Fleming on 04/27/2026 and notes holdings reflect securities held by certain Reporting Business Units of BlackRock.
Anteris Technologies Global Corp. files a prospectus supplement updating its Registration Statement to cover the resale of up to 9,103,796 shares of Common Stock by the selling stockholders named in the Prospectus. The supplement attaches a Form 8-K reporting a new lease.
The Form 8-K discloses a lease through a wholly owned subsidiary for approximately 181,436 square feet in Brooklyn Park, Minnesota, with an initial term from September 1, 2026 to August 31, 2037. The lease specifies an initial monthly minimum rent of $152,708.63, contractual rent abatements (first three months fully abated, succeeding nine months partially abated), annual escalations, and payment of taxes and operating expenses. The lease description is qualified by the full lease to be filed as an exhibit to the Company’s Form 10-Q.
Anteris Technologies Global Corp. has entered into a long-term lease for approximately 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, through its wholly owned subsidiary Anteris Technologies Corporation.
The lease starts on September 1, 2026 and runs through August 31, 2037, with options to extend for two additional 84‑month periods at market rent. Initial monthly minimum rent is $152,708.63, subject to contractual abatements, annual escalations and other adjustments, plus real estate taxes, operating expenses and other charges. Rent is fully abated for the first three months and partially abated for the following nine months, which eases cash outlay during the initial occupancy period.
Anteris Technologies Global Corp. registers 9,103,796 shares for resale by selling stockholders. The registration covers up to 9,103,796 shares of Common Stock, comprised of 2,346,936 Shares, 2,346,936 Common Stock Warrant Shares, 2,079,962 CDI Shares and 2,329,962 CDI Warrant Shares.
The prospectus states the Company will not receive proceeds from secondary resales but may receive up to $40.4 million in aggregate gross proceeds if the Warrants are exercised. The filing describes the 2025 Private Placement, the 2026 Public Offering and the Medtronic private placement, and includes selling stockholder tables and plan of distribution methods.
Anteris Technologies Global Corp. is registering the resale of 9,103,796 shares of Common Stock pursuant to a post-effective amendment to its Form S-1.
The registration covers (i) 2,346,936 Shares, (ii) 2,346,936 Common Stock Warrant Shares, (iii) 2,079,962 CDI Shares, and (iv) 2,329,962 CDI Warrant Shares. The Company states it will not receive proceeds from resale by the selling stockholders, but may receive up to $40.4 million in aggregate gross proceeds upon exercise of the Warrants. Shares outstanding were 36,062,370 as of September 30, 2025.
This Post-Effective Amendment No. 1 incorporates by reference the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and confirms no additional securities are being registered in this amendment.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported an equity award in the form of 78,740 Restricted Stock Units (RSUs) on March 4, 2026. The RSUs were acquired as a grant at a price of $0.0000 per unit, increasing his direct derivative holdings to 78,740 RSUs.
Each RSU represents a right to receive one CHESS Depositary Interest (CDI), and each CDI represents an interest in one share of Anteris common stock. The RSUs vest in three approximately equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to McDonnell’s continued service through each vesting date.
Anteris Technologies Global Corp. disclosed that its Compensation Committee approved a one-time, discretionary grant of restricted stock units (RSUs) to Chief Financial Officer Matthew McDonnell. The award has a target value of $500,000, with the exact number of RSUs set by the closing price of the Company’s common stock on March 4, 2026, the grant date.
One-third of the RSUs will vest on each of the first three anniversaries of the grant date, contingent on Mr. McDonnell’s continued employment. The RSUs fully vest earlier if he dies, becomes permanently disabled, or experiences certain terminations in connection with a change in control. Once vested, the RSUs will be settled in CHESS depositary interests of the Company and are described as a special award that does not change his 2026 annual equity target.